← Leaderboards
Jonathan R Sanders
Generx+, Inc.
$983,097
Attributed
$983,097
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$983,097 · 3
By mechanism
R44$785,508 · 1
R43$197,589 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Transfection /Expression Vector”
- William W Hauswirth · University Of Florida$14,472,513
- Kenneth G Cornetta · Indiana Univ-Purdue Univ At Indianapolis$10,466,261
- Klaus H. Kaestner · University Of Pennsylvania$8,467,407
- David T Curiel · University Of Alabama At Birmingham$8,321,535
- Timothy A Cross · Florida State University$7,979,166
- John H Wolfe · Children'S Hospital Of Philadelphia$7,103,743
Research focus
Transfection /Expression VectorBiotechnologyInhalation Drug AdministrationGene ExpressionGene TargetingGene TherapyAerosolsLiposomesPlasmidsSheepTechnology /Technique DevelopmentTissue /Cell CultureGene Delivery SystemNonhuman Therapy EvaluationProstaglandin Endoperoxide SynthasePulmonary HypertensionDisease /Disorder Prevention /ControlRespiratory Disease /Disorder TherapyEnzyme Linked Immunosorbent AssayEvaluation /TestingAlpha 1 AntitrypsinDrug Administration Rate /DurationTherapy Design /DevelopmentLung Disorder
Grant awards (4)
Development of Alpha-1 Antitrypsin Gene Therapeutic as Treatment for COPD$97,589
R43 · FY2005 · HL
Improved Plasmid/Liposome Administration to the Lungs$331,532
R44 · FY2003 · HL
Improved Plasmid/Liposome Administration to the Lungs$453,976
R44 · FY2002 · HL
IMPROVED PLASMID/LIPOSOME ADMINISTRATION TO THE LUNGS$100,000
R43 · FY2000 · HL